Related Experiment Videos

Hodgkin's lymphoma. II: Treatment and delayed morbidity

¹Service de Médecine, CS Axel Unit, Institut Gustave-Roussy, Villejuif, France.

BMJ (Clinical Research Ed.)

|July 18, 1992

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposure.

Radiation protection dosimetry·2014

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin's lymphoma patients and poor clinical outcome.

Annals of oncology : official journal of the European Society for Medical Oncology·2009

Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

Leukemia & lymphoma·2005

Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.

Leukemia & lymphoma·2004

Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.

European journal of cancer (Oxford, England : 1990)·2004

See all related articles